Adherence level of antihypertensive agents in coronary artery disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Non‐adherence is probably an important source of preventable cardiovascular morbidity and mortality. • However, until now there have been very few large effectiveness studies assessing the relationship between adherence levels to antihypertensive medication and major cardiovascular outcomes for primary prevention of cardiovascular disease. WHAT THIS STUDY ADDS • The study results suggest that there is an association between better adherence to antihypertensive agents and a relative risk reduction of coronary artery disease. • Adherence to antihypertensive agents needs to be improved so that patients can benefit from the full protective effects of antihypertensive therapies. AIMS Antihypertensive (AH) agents have been shown to reduce the risk of cardiovascular events, including coronary artery disease (CAD). Previous surveys have shown that a substantial number of patients with diagnosed hypertension remain uncontrolled. Non‐adherence to AH agents may reduce the effectiveness. The aim was to evaluate the impact of better adherence to AH agents on the occurrence of CAD in a real clinical setting. METHODS A cohort of 83 267 patients was reconstructed using the Régie de l'assurance maladie du Québec databases. Patients were eligible if they were between 45 and 85 years of age without indication of cardiovascular disease, and had been newly treated with AH agents between 1999 and 2004. A nested case–control design was used to study the incidence of CAD. Every case of CAD was matched for age and duration of follow‐up to up to 15 randomly selected controls. The adherence level was measured by calculating the medication possession ratio. Cases' adherence was calculated from the start of follow‐up to the time of the CAD (index date). For controls, adherence was calculated from the start of follow‐up to the time of selection (index date). Rate ratios of CAD were estimated by conditional logistic regression adjusting for covariables. RESULTS The mean patient age was 65 years, 37% were male, 8% had diabetes and 18% had dyslipidaemia. High adherence level (96%) to AH therapy compared with lower adherence level (59%) was associated with a relative risk reduction of CAD events (rate ratios 0.90; 0.84, 0.95). Risk factors for CAD were male gender, diabetes, dyslipidaemia and developing a cardiovascular condition disease during follow‐up. CONCLUSION Our study suggests that better adherence to AH agents is associated with a risk reduction of CAD. Adherence to AH agents needs to be improved so that patients can benefit from the full protective effects of AH therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
Essebag, V., Platt, R. W., Abrahamowicz, M., & Pilote, L. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-5 · Cited by 234
Cited by
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Better compliance to antihypertensive medications reduces cardiovascular risk
Corrao, G., Parodi, A., Nicotra, F., Zambon, A., Merlino, L., Cesana, G., & Mancia, G. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328342ca97 · Cited by 367
Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs
Dragomir, A., Côté, R., Roy, L., Blais, L., Lalonde, L., Bérard, A., & Perreault, S. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d567bd · Cited by 221
Self-citationDrug adherence in hypertension: from methodological issues to cardiovascular outcomes
Hamdidouche, I., Jullien, V., Boutouyrie, P., Billaud, E., Azizi, M., & Laurent, S. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001299 · Cited by 111
Metadata
- Authors
- Perreault, S., Dragomir, A., Roy, L., White, M., Blais, L., Lalonde, L., & Bérard, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-12-23
- Volume
- 69
- Issue
- 1
- Pages
- 74-84
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1975122293
- Cited by
- 72
- References
- 6
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adherence level of antihypertensive agents in coronary artery disease. https://app.cochat.ai/papers/10.1111/j.1365-2125.2009.03547.x
- The paper
- Perreault, S., Dragomir, A., Roy, L., White, M., Blais, L., Lalonde, L., & Bérard, A. (2010). Adherence level of antihypertensive agents in coronary artery disease. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03547.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.